Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and long-term development [1] Group 1: Share Buyback - On January 28, Yidu Tech announced a share buyback of 204,000 shares at approximately HKD 6 per share, costing around HKD 1.23 million [1] - The company has conducted share buybacks for three consecutive trading days, totaling approximately 709,000 shares repurchased and over HKD 4.2 million spent [1] Group 2: Business Progress - The number of insured individuals under the 2026 Beijing Universal Health Insurance program has surpassed 4.5 million, showcasing the company's operational strength and market recognition [1] - Yidu Tech has been the main operating platform for this project for five consecutive years, contributing to the multi-tiered medical security system in the capital [1] Group 3: International Collaboration and Recognition - The founder and chairman of Yidu Tech, Gong Rujing, attended the 2026 Winter Davos Forum, where a collaboration with Novartis Foundation and the Brunei Ministry of Health was announced for a cardiovascular disease prevention project called CARDIO4Cities [1] - Yidu Tech ranked first in the 2025 Medical Big Data Company Rankings for the seventh consecutive year, reflecting its strong technical foundation, mature product system, and extensive industry experience [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback on January 28, repurchasing 204,000 shares at approximately HKD 6 per share, totaling around HKD 1.23 million [1] - This marks the third consecutive trading day of intensive buyback operations, with a total of approximately 709,000 shares repurchased and over HKD 4.2 million spent, demonstrating the company's confidence in its intrinsic value and long-term development [1] - The company's main business has also shown progress, with the number of insured individuals in the 2026 Beijing Universal Health Insurance project exceeding 4.5 million, highlighting its operational strength and market recognition [1] Group 2 - The founder and chairman of the company, Gong Rujing, was recently invited to attend the 2026 Winter Davos Forum, where a collaboration was announced between the Novartis Foundation, the Brunei Ministry of Health, and the company's subsidiary, EVYD, to implement a data-driven cardiovascular disease prevention project called CARDIO4Cities, expanding its international cooperation [1] - The company was ranked first in the authoritative list of the "2025 Medical Big Data Companies," marking its seventh consecutive year at the top, showcasing its strong technical foundation, mature product system, and extensive industry experience [1]

Core Viewpoint - The company, Yidu Tech (02158), is actively engaging in share buybacks and has recently announced significant partnerships and achievements in the healthcare data industry [1] Share Buyback Activity - On January 27, Yidu Tech repurchased approximately 378,600 shares at a price of around HKD 6 per share, totaling nearly HKD 2.3 million [1] - The company has conducted buybacks for two consecutive days, accumulating a total of 505,000 shares repurchased and over HKD 3 million in total buyback amount [1] Industry Engagement and Partnerships - Yidu Tech's founder and chairman, Gong Rujing, participated in the 2026 Winter Davos Forum, engaging in high-level industry dialogues and meetings with global leaders [1] - At the forum, a significant collaboration was announced involving the Novartis Foundation, the Brunei Ministry of Health, and Yidu Tech's subsidiary, EVYD, to implement a smart-driven cardiovascular disease prevention project called CARDIO4Cities [1] Industry Recognition - Yidu Tech has been recognized as the top company in the "2025 Medical Big Data Company Rankings," marking its seventh consecutive year at the top, reflecting its strong technological foundation, mature product system, and extensive industry experience [1]

Group 1 - The company, Yidu Tech (02158), repurchased 378,600 shares at approximately HKD 6 per share on January 27, totaling nearly HKD 2.3 million, marking the second consecutive day of buybacks, with a cumulative total of 505,000 shares and over HKD 3 million in total repurchase amount [1] - The founder and chairman of the company, Gong Rujing, attended the 2026 Winter Davos Forum, engaging in high-level industry dialogues and meetings with global leaders from politics, business, and academia [1] - At the forum, a significant collaboration was announced involving Novartis Foundation, the Brunei Ministry of Health, and Yidu Tech's subsidiary EVYD, aimed at implementing a data-driven cardiovascular disease prevention project called CARDIO4Cities [1] Group 2 - The company has been recognized as the top performer in the "2025 Medical Big Data Company Rankings," marking its seventh consecutive year at the top, reflecting its strong technological foundation, mature product system, and extensive industry experience [1]

Group 1: Industrial Policy and Technological Advancements - The Ministry of Industry and Information Technology has issued a revised management approach for public service platforms in industrial technology, effective from December 5, 2025, emphasizing the need for service platforms to enhance their capabilities and optimize service quality [1][1] - Inner Mongolia Geological and Mineral Group has developed the first specialized dataset for mineral exploration using AI technology, marking a significant advancement in intelligent geological exploration [1][5] Group 2: Food Safety and Digital Innovation - Heilongjiang Province has implemented digital food labels for 105 products, enhancing consumer information accessibility and promoting food safety through interactive features [2][5] - The initiative aims to improve consumer awareness and support food enterprises through increased promotion and technical guidance [2][5] Group 3: Meteorological Data and Flood Risk Management - The Henan Meteorological Bureau has developed a dataset for typical flood events in the Yellow River basin, which has passed the national approval process, enhancing flood risk prediction and management capabilities [3][6] - This dataset integrates various data sources to improve the accuracy of flood risk assessments and extend the forecasting period [3][6] Group 4: Social Science and AI Integration - A new AI model for social sciences has been launched in Hubei, featuring a dedicated interactive robot and a team of digital social science experts, marking a significant step in integrating AI with social research [4][7] - The AI platform is designed to support data sharing and collaborative research, ensuring rigorous academic standards [4][7] Group 5: Healthcare Data Management - The establishment of the first provincial-level big data center for healthcare in Hainan aims to break down data barriers among healthcare, insurance, and pharmaceutical sectors, facilitating better service delivery [5][7] - This center is expected to enhance the efficiency of healthcare processes and support regulatory compliance in drug safety and medical practices [5][7]

Core Viewpoint - Guoxin Health is actively collaborating with insurance brokerage firms, health management service providers, and medical service institutions to explore a data-driven full-chain service model for health insurance, covering product design, marketing, underwriting, claims, and risk control [2] Group 1: Collaboration and Innovation - The company has established deep cooperative relationships with several domestic insurance companies to promote the implementation of innovative health insurance service models [2] - Guoxin Health is involved in projects such as the operation of public data authorization in Hangzhou and the personal medical insurance data authorization query in Pingxiang, Jiangxi, to enhance data compliance and operational practices [2] Group 2: Data Integration and Development - Guoxin Health has jointly established a company with Hubei Data Group to operate health medical big data in Central China, aiming to integrate and utilize health medical data resources within Hubei Province [2] - The newly formed company serves as a pilot for public data authorization operations in the "Three Medical" fields, facilitating the development and utilization of health medical data resources [2]

Core Insights - The construction of a national-level trusted data space for the pharmaceutical industry will follow three main strategies: government-enterprise co-management, pilot projects in subspaces, and a whitelist approach for gradual implementation [1][2] Group 1: Data Governance in Pharmaceutical Industry - The trusted data space is based on the drug traceability platform launched in 2023, which integrates data across the entire chain of drug production, distribution, and usage [1] - The focus will initially be on mature areas such as biological products, medical devices, and anesthetic drugs, with steady progress being made in these areas [1] Group 2: AI and Healthcare - Key breakthrough areas for AI in healthcare include innovative drug development, intelligent health management, and medical diagnostic assistance [1] - The potential for AI to enhance health management services and reduce misdiagnosis rates is significant, facilitated by the integration of health data [1] Group 3: Collaboration with Guizhou - The company anticipates that the Digital Expo will play a role in policy guidance, standard setting, and ecosystem collaboration within the healthcare big data sector [2] - Future collaboration with Guizhou will focus on integrating industry data spaces with urban data spaces and implementing a personal health account system [2]